Inhibikase Therapeutics Inc (IKT)

Überblick Nachrichten Preisverlauf Financials Forum Prognose Aktiensplit

Finanzdaten der Inhibikase Therapeutics Inc-Aktie (IKT)

*Alle Zahlen in Millionen

Enddatum des Zeitraums	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Periodenlänge	3 Monate	3 Monate	3 Monate	3 Monate	3 Monate
Revenues	-	-	-	-	-
Selling, General, and Administrative	5.21% 5.6115	5.9197	5.2493	5.7351	1.6376
Costs And Expenses	17.87% 12.77	10.83	14.60	12.93	5.8275
Provision For Loan, Lease, And Other Losses	-	-	-	-	-
Operating Income/Loss	17.87% -12.77	-10.83	-14.60	-12.93	-5.8275
Net Interest Income/Expense	8.58% 0.8381	0.9168	0.9193	0.7961	0.0494
Interest Income/Expense After Provision For Losses	8.58% 0.8381	0.9168	0.9193	0.7961	0.0494
Income/Loss From Continuing Operations Before Tax	28.77% -12.77	-9.9155	-13.68	-12.93	-5.8275
Income Tax Expense/Benefit	-	-	-	-	-
Income/Loss From Continuing Operations After Tax	20.32% -11.93	-9.9155	-13.68	-12.13	-5.7781
Net Income/Loss	20.32% -11.93	-9.9155	-13.68	-12.13	-5.7781
Preferred Stock Dividends And Other Adjustments	-	-	-	-	-
Attributable To Noncontrolling Interest	-	-	-	-	-
Basic Average Shares	0.05% 90.05	90.01	89.54	16.12	8.8826
Diluted Average Shares	0.05% 90.05	90.01	89.54	16.12	8.8826
Basic Earnings Per Share	18.18% -0.13	-0.11	-0.15	0.87	-0.65
Diluted Earnings Per Share	18.18% -0.13	-0.11	-0.15	0.87	-0.65
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic	-	-	-	-	-

RPRX

$45.65

0.48%

ROIV

$28.06

1.72%

MRNA

$52.56

1.55%

BNTX

$91.19

1.21%

INSM

$139.50

0.01%

ONC

$284.05

0.44%